Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.4.1281

Prognostic Factors for Second-line Treatment of Advanced Non-small-cell Lung Cancer: Retrospective Analysis at a Single Institution  

Inal, Ali (Department of Medical Oncology, Dicle University)
Kaplan, M. Ali (Department of Medical Oncology, Dicle University)
Kucukoner, Mehmet (Department of Medical Oncology, Dicle University)
Urakci, Zuhat (Department of Medical Oncology, Dicle University)
Karakus, Abdullah (Department of Internal Medicine, Dicle University)
Isikdogan, Abdurrahman (Department of Medical Oncology, Dicle University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.4, 2012 , pp. 1281-1284 More about this Journal
Abstract
Background: Platinum-hased chemotherapy for advanced non-small cell lung cancer (NSCLC) is still considered the first choice, presenting a modest survival advantage. However, the patients eventually experience disease progression and require second-line therapy. While there are reliable predictors to identify patients receiving first-line chemotherapy, very little knowledge is available about the prognostic factors in patients who receive second-line treatments. The present study was therefore performed. Methods: We retrospectively reviewed 107 patients receiving second-line treatments from August 2002 to March 2012 in the Dicle University, School of Medicine, Department of Medical Oncology. Fourteen potential prognostic variables were chosen for analysis in this study. Univariate and multivariate analyses were conducted to identify prognostic factors associated with survival. Result: The results of univariate analysis for overall survival (OS) were identified to have prognostic significance: performance status (PS), stage, response to first-line chemotherapy response to second-line chemotherapy and number of metastasis. PS, diabetes mellitus (DM), response to first-line chemotherapy and response to second-line chemotherapy were identified to have prognostic significance for progression-free survival (PFS). Multivariate analysis showed that PS, response to first-line chemotherapy and response to second-line chemotherapy were considered independent prognostic factors for OS. Furthermore, PS and response to second-line chemotherapy were considered independent prognostic factors for PFS. Conclusion: In conclusion, PS, response to first and second-line chemotherapy were identified as important prognostic factors for OS in advanced NSCLC patients who were undergoing second-line palliative treatment. Furthermore, PS and response to second-line chemotherapy were considered independent prognostic factors for PFS. It may be concluded that these findings may facilitate pretreatment prediction of survival and can be used for selecting patients for the correct choice of treatment.
Keywords
Non-small cell lung cancer; prognostic factors; second-line treatment;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ciuleanu T, Stelmakh L, Clicenas S, et al(2012). Efficacy and safety of erlotinib versus chemotherapy in secondline treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol, 13, 300-8.   DOI   ScienceOn
2 Di Maio M, Lama N, Morabito A, et al (2010). Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Eur J Cancer, 46, 735-43   DOI
3 Di Maio M, Krzakowski M, Fougeray R, Kowalski DM, Gridelli C (2012). Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: External validation in a phase III trial comparing vinflunine with docetaxel. Lung Cancer, Feb 21
4 Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8.   DOI   ScienceOn
5 Hanna N, Shepherd FA, Fossella FV, et al (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 22, 1589-97.   DOI   ScienceOn
6 Hotta K, Fujiwara Y, Kiura K, et al (2007). Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thoracic Oncol, 2, 402-7.   DOI
7 Kim JG, Ryoo BY, Park YH, et al (2008). Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol, 61, 301-7.
8 Krishnan S, Rana V, Janjan NA, et al (2006). Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer, 107, 2589-96.   DOI   ScienceOn
9 Mitry E, Douillard JY, Van Cutsem E, et al (2004). Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trial. Ann Oncol, 15, 1013-7.   DOI
10 Scartozzi M, Mazzanti P, Giampieri R, et al (2010). Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: selecting the unselectable? Lung Cancer, 68, 433-7.   DOI
11 Shepherd FA (1993). Screening, diagnosis, and staging of lung cancer. Curr Opin Oncol, 5, 310-22.   DOI
12 Zietemann V, Duell T (2011). Prevalence and effectiveness of first-, second-, and third-line systemic therpy in a cohort of unselected patients with advanced non-small cell lung cancer. Lung Cancer, 73, 70-7.   DOI
13 Wataya H, Okamoto T, Maruyama R, et al (2009). Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib. Lung Cancer, 64, 341-5.   DOI
14 Azzoli CG, Baker Jr S, Temin S, et al (2009). American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol, 27, 6251-66.   DOI
15 Boyle P, Ferlay J (2004). Cancer incidence and mortality in Europe. Ann Oncol, 16, 481-8.
16 Weiss GJ, Rosell R, Fossella F, et al (2007). The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol, 18, 453-60.